Craig S Conoscenti MD FCCP, ATSF
Interstitial Lung Diseases, Restrictive Lung Disease
Sr. VP, Clinical Development Avalyn Pharma, Inc
Join to View Full Profile
Sr. VP, Clinical DevelopmentAvalyn Pharma, IncSeattle, WA 98101
Phone+1 203-482-3219
Dr. Conoscenti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Norwalk HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 1985 - 1987
Hackensack University Medical CenterChief Residency, Internal Medicine, 1984 - 1985- Hackensack University Medical CenterResidency, Internal Medicine, 1982 - 1984
New York-Presbyterian Brooklyn Methodist HospitalInternship, Internal Medicine, 1981 - 1982
St. George's University School of MedicineClass of 1981
Certifications & Licensure
CT State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease.Rohit Aggarwal, Chester V Oddis, Daniel I Sullivan, Siamak Moghadam-Kia, Didem Saygin
BMC Pulmonary Medicine. 2024-10-30 - Proportion and predictors of FVC decline in patients with interstitial lung disease.Maeve G Macmurdo, Xinge Ji, Pratik Pimple, Amy L Olson, Alex Milinovich
Respiratory Medicine. 2024-06-01 - 2 citationsImpact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization.David Singer, Benjamin Chastek, Andrew Sargent, Jonathan C Johnson, Sharash Shetty
BMC Pulmonary Medicine. 2023-09-09
Journal Articles
- Stability or Improvement in Forced Vital Capacity with Nintedanib in Patients with IPFKevin R Flaherty, Craig S Conoscenti, The European Respiratory Journal
Press Mentions
American Lung Association Announces New Support for Landmark Lung Health Cohort StudyJune 15th, 2021- Study Analysis Available During ATS 2021 Supports Long-Term Treatment with Ofev® in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseMay 14th, 2021
- 1st Patient Enrolled in Trial Testing Ofev on Post-COVID-19 PFNovember 23rd, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
